T-lymphocytes and cytokines in sarcoidosis

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 5, 2002, Pages 435-440

  Agostini, Carlo ^a,b   Meneghin, Alessia ^a   Semenzato, Gianpietro ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; GAMMA INTERFERON; HLA DR3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; RANTES; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; GRANULOMA; HUMAN; IMMUNOPATHOGENESIS; LOWER RESPIRATORY TRACT; LUNG LAVAGE; LYMPHOCYTE FUNCTION; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SARCOIDOSIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0036320837     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200209000-00016     Document Type: Review

References (37)

1. Immune mechanisms in interstitial lung diseases
2. Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation
3. Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis
4. TH1/TH2 and TC1/TC2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis
5. Cells and molecules involved in the development of sarcoid granuloma
6. + lung and blood T cells in sarcoidosis
7. Sarcoidosis: Developments in etiology, immunology, and therapeutics
8. T-cell receptor genes in sarcoidosis
9. +) lung T-cell expansions in pulmonary sarcoidosis
10. Specific bronchoalveolar lavage fluid T cells associate with disease in a pair of monozygotic twins discordant for sarcoidosis
11. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions
12. Increased macrophage inflammatory protein-1 alpha and maerophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis
13. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: Involvement of macrophages and endothelial cells
14. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases
15. ELevated levels of thymus- and activation-regulated Chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia
16. Expression of IL-15 in inflammatory pulmonary diseases
17. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis
18. Interleukin-16
19. CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis
20. Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis
21. + cells
22. Immunologic mechanisms in granulomatous lung disease
23. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs
24. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro
25. Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation
26. Th1/Th2 cell distribution in pulmonary sarcoidosis
27. ATS/ERS/WASOG statement on sarcoidosis
28. Cell apoptosis and granulomatous lung diseases
29. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis
30. Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease
31. Functional genomics in sarcoidosis-reduced or increased apoptosis?
32. + T lymphocyte activation in sarcoidosis
33. Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-kappa b- dependent signaling pathways
34. NF-kappaB activation in sarcoidosis
35. Cytokine and chemokine blockade as immunointervention strategy for the treatment of diffuse lung diseases
36. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy
37. Infliximab for refractory sarcoidosis